Is there strong evidence for polynucleotides in intimate dryness?
Is there strong evidence for polynucleotides in intimate dryness? Not yet. Small, early studies suggest potential improvements in comfort and hydration, but trials are few, short, and methodologically varied. Compared with guideline-backed options like moisturisers, lubricants and low-dose local vaginal oestrogen, the evidence for polynucleotides is limited. If considered, they should follow a stepwise plan with clear goals, aftercare and review. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
Is there strong evidence for polynucleotides in intimate dryness? At present, no robust, long-term evidence. Polynucleotides (PN)—highly purified DNA/RNA fragments, often salmon-derived—are proposed as “biostimulators” for mucosal hydration and surface comfort. In genitourinary syndrome of menopause (GSM), also called vaginal atrophy, a few small studies have explored PN injections or gels for symptoms such as dryness, burning and dyspareunia. Results can be encouraging in the short term, but the research base is still limited: small sample sizes, varied formulations and dosing, short follow-up and a lack of adequately powered, sham-controlled comparisons with guideline-supported care (for example, low-dose local vaginal oestrogen).
Where PN might fit—if at all. GSM has both a biology component (low oestrogen → thinner epithelium, higher pH, fewer Lactobacillus) and a mechanics component (friction → micro-tears, dyspareunia). First-line steps target both: a scheduled vaginal moisturiser 2–4 nights weekly, a generous compatible lubricant for higher-friction moments, and—when symptoms affect quality of life—low-dose local vaginal oestrogen (or vaginal DHEA) guided by national recommendations. If these are optimised yet vestibular sting and “paper-cut” splits persist, a clinician may discuss adjunctive options such as vestibule-targeted therapies. PN would be considered in that adjunct space and only with informed consent about uncertainties.
Safety and suitability. PN products are generally well tolerated in aesthetic/dermatology contexts, but intimate use warrants extra caution. People with severe fish allergy may be unsuitable for salmon-derived formulations. Those on anticoagulants may bruise more after injections and need an individual plan. Active infection (BV, thrush, UTI), malodorous discharge, fever, or new post-menopausal bleeding are reasons to defer and prioritise diagnosis. Any unexpected reactions should be reported via appropriate UK channels. PN, if used, should not replace foundations or local hormonal therapy when these are acceptable and effective.
Real-world expectations. If tried, PN is often delivered as a short series (for example, 2–3 sessions spaced 4–8 weeks apart) with a review 6–12 weeks later. Tenderness or pinpoint bruising can occur short-term; most people pause high-friction activity and intimacy until settled (commonly 3–5 days). Comfort gains—if any—should be judged against practical outcomes (fewer micro-tears, less urine sting, easier initial penetration), not just a clinic score.
How to proceed stepwise. Begin with evidence-backed foundations and correct placement: if soreness is entrance-focused, place moisturiser or oestrogen cream at the vestibule and posterior fourchette as well as internally; before higher-friction activities, smooth a pea of lubricant directly at the entrance and inside. Many people improve here without procedures. For a practical overview of sequencing, see how treatment steps are sequenced and what improvements to look for under treatment benefits.
Bottom line. There is emerging but limited evidence for polynucleotides in intimate dryness. Discuss uncertainties, costs and maintenance needs, and only consider PN after an excellent trial of moisturiser/lubricant plus local oestrogen (or DHEA) where acceptable. Keep expectations conservative and decisions anchored to your day-to-day comfort and goals.
Clinical Context
Who might consider PN? People with vestibular sting and micro-tears that persist despite a scheduled moisturiser, a well-matched lubricant (silicone-based often gives the longest glide), and accurate placement of local oestrogen/DHEA. PN would be an adjunct, not a first-line therapy.
Who should avoid or delay? Anyone with suspected infection, malodorous discharge, fever, new post-menopausal bleeding, or recent pelvic/perineal surgery without clearance. Severe fish allergy generally excludes salmon-derived PN. People on anticoagulants should expect more bruising with injections and need an individualised plan.
Alternatives and next steps. Optimise foundations first: moisturiser 2–4 nights weekly, generous compatible lubricant every higher-friction moment, fragrance-free skincare, breathable fabrics, and chlorine rinse-off after swimming. If acceptable, local oestrogen/DHEA typically improves dryness and soreness within 2–6 weeks. Consider pelvic health physiotherapy and graded dilators where pelvic floor guarding is part of the picture.
Evidence-Based Approaches
NHS overview (patient-facing): Plain-English advice on symptoms, moisturisers, lubricants and when to seek help for vaginal dryness anchors first steps and red flags.
NICE guidance (UK): The NICE Menopause Guideline (NG23) recommends offering vaginal moisturisers and lubricants and considering low-dose local vaginal oestrogen when quality of life is affected, with or without systemic HRT.
Prescribing detail: Dosing and cautions for licensed local vaginal oestrogens and prasterone (DHEA) are set out in the British National Formulary (BNF), supporting safe technique (including vestibule-aware placement) and long-term, lowest-effective maintenance.
Comparative effectiveness benchmarks: Systematic reviews in the Cochrane Library show local vaginal oestrogens improve dryness, soreness, dyspareunia and vaginal pH versus placebo—useful context when weighing newer adjuncts like PN.
Pathophysiology & research landscape: Peer-reviewed overviews on PubMed summarise GSM mechanisms and highlight that evidence for non-hormonal injectable adjuncts (including PN) remains limited and heterogeneous, underscoring the importance of shared decision-making.